Become A Featured Company

NanoSphere Health Science’s Evolve Formulas NanoSerum™ Shows Promise According to Users

Rachelle Gordon

July 11th, 2018

Exclusive, News, Top Story

NanoSphere Health Sciences Inc. (CSE: NSHS) is on the cutting-edge of cannabinoid delivery science with its patented NanoSphere Delivery System™. Its cannabis brand, Evolve Formulas, has commercialized this delivery platform through its pioneering product, NanoSerum™, which uses one-of-a-kind nanotechnology to encapsulate cannabinoids in lipid membranes for direct delivery through the skin and into the circulatory system within minutes for rapid and effective relief from pain, inflammation and anxiety. The product has been called life-changing by some, opening new doors for people exploring alternatives to more conventional treatments.

David Sutton, COO of NanoSphere, knew they had something special after his mother tried an early formulation of Evolve Formulas NanoSerum™ to help ease symptoms of Crohn’s disease.

“When we were in the initial R&D stage of applying our technology to cannabis, we had a couple of prototypes, and my father – CEO of NanoSphere – brought one home. My mom had a Crohn’s attack about to begin, and when that happens, she gets a lot of spasms in her GI tract, and it’s extraordinarily painful, and it lasts for up to 12 hours. My father said, ‘Why don’t you just try this?’ Not even really thinking about it, just trying to give her some relief. She rubbed it on her stomach and her abdomen, and within a minute her spasms stopped, and they did not return.”

Sutton calls the effects “incredible,” stating that no mainstream medication he’d heard of had ever been able to do what the NanoSerum™ did.

“From there, we went full force into creating the best product we could,” he explains.

Emily Anderson, a 21-year-old college student, began using NanoSerum™ after being told about it by a friend. Anderson has suffered from extreme PTSD following a sexual assault in 2015.

“It was the only thing that ever actually worked,” she tells CFN Media. “I’ve been on so many different medications, the majority of which had terrible side-effects, but NanoSerum™ has given me my life back.” Anderson states she uses the product for both anxiety and to help combat shoulder pain that she believes is exacerbated by her PTSD.

“NanoSerum™ is anxiety relieving, but the pain relief in my shoulders is the most important benefit. Anxiety causes loads of knots in my shoulders and Evolve Formulas products help to soothe the pain.”

 

Sutton says it’s stories like these that keep him motivated to continue to develop NanoSphere’s technology and product line. He mentions an elderly patient with degenerative disc disease who was able to completely wean himself off of fentanyl, an extremely dangerous opioid painkiller that is blamed for the accidental overdose deaths of both Prince and Tom Petty.

“More and more of these stories are coming out. It’s inspiring to hear that you’re helping create something that’s really improving people’s lives.” He mentions a women suffering from arthritis so severe she couldn’t use her hand who had tried other cannabis topicals with no success.

“Within minutes of trying our product, she was able to move her hand again, which she hadn’t been able to do previously,” Sutton explains. “After consistent usage, she can actually use her hand. Not only move it, but write with it again, and she said it’s been years since she’s been able to do that.”

These stories are just a few of the many being told every day and the team at NanoSphere Health Sciences wants to ensure they continue. Pre-sales of their new Evolve CBD formula have recently begun and intranasal and intraoral products are currently in development. Initial tests on the intranasal spray show on-set within 80 seconds, which Sutton believes will be crucial for patients who need immediate results.

“We believe the intranasal will be as beneficial to people with PTSD just as people with arthritis find our NanoSerum. We’re very excited to see how it’s going to impact lives.”

Learn more about NanoSphere Health Sciences Inc. (CSE: NSHS) by visiting their website or downloading their investor presentation.

Disclaimer

The above article is sponsored content. Emerging Growth LLC, which owns CannabisFN.com and CFN Media, has been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: https://cannabisfn.com/legal-disclaimer/

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Rachelle Gordon

Rachelle Gordon is a Minneapolis-based writer. Find her online at www.rachellegordon.net.

Network Partners

Follow Us on Social Media

LinkedIn

About CFN Media Group

CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.

Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.

Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer

loading